111 related articles for article (PubMed ID: 21255760)
21. Final 5-year results of the TAXUS II trial: a randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for de novo coronary artery lesions.
Silber S; Colombo A; Banning AP; Hauptmann K; Drzewiecki J; Grube E; Dudek D; Baim DS
Circulation; 2009 Oct; 120(15):1498-504. PubMed ID: 19786634
[TBL] [Abstract][Full Text] [Related]
22. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial.
von Birgelen C; Basalus MW; Tandjung K; van Houwelingen KG; Stoel MG; Louwerenburg JH; Linssen GC; Saïd SA; Kleijne MA; Sen H; Löwik MM; van der Palen J; Verhorst PM; de Man FH
J Am Coll Cardiol; 2012 Apr; 59(15):1350-61. PubMed ID: 22341737
[TBL] [Abstract][Full Text] [Related]
23. 1-year clinical outcomes of diabetic patients treated with everolimus-eluting bioresorbable vascular scaffolds: a pooled analysis of the ABSORB and the SPIRIT trials.
Muramatsu T; Onuma Y; van Geuns RJ; Chevalier B; Patel TM; Seth A; Diletti R; García-García HM; Dorange CC; Veldhof S; Cheong WF; Ozaki Y; Whitbourn R; Bartorelli A; Stone GW; Abizaid A; Serruys PW; ; ; ; ; ;
JACC Cardiovasc Interv; 2014 May; 7(5):482-93. PubMed ID: 24746650
[TBL] [Abstract][Full Text] [Related]
24. Everolimus-eluting stents in patients undergoing percutaneous coronary intervention: final 3-year results of the Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions trial.
Brener SJ; Kereiakes DJ; Simonton CA; Rizvi A; Newman W; Mastali K; Wang JC; Caputo R; Smith RS; Ying SW; Cutlip DE; Stone GW
Am Heart J; 2013 Dec; 166(6):1035-42. PubMed ID: 24268218
[TBL] [Abstract][Full Text] [Related]
25. Five-year long-term clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery disease: the SPIRIT II trial.
Onuma Y; Miquel-Hebert K; Serruys PW;
EuroIntervention; 2013 Jan; 8(9):1047-51. PubMed ID: 23339811
[TBL] [Abstract][Full Text] [Related]
26. TAXUS VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions.
Grube E; Dawkins KD; Guagliumi G; Banning AP; Zmudka K; Colombo A; Thuesen L; Hauptman K; Marco J; Wijns W; Popma JJ; Buellesfeld L; Koglin J; Russell ME
Eur Heart J; 2007 Nov; 28(21):2578-82. PubMed ID: 17938126
[TBL] [Abstract][Full Text] [Related]
27. Long-term safety and efficacy of the everolimus-eluting stent compared to first-generation drug-eluting stents in contemporary clinical practice.
Barbash IM; Minha S; Torguson R; Ben-Dor I; Badr S; Loh JP; Satler LF; Pichard AD; Waksman R
J Invasive Cardiol; 2014 Apr; 26(4):154-60. PubMed ID: 24717271
[TBL] [Abstract][Full Text] [Related]
28. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial.
Stone GW; Ellis SG; Cox DA; Hermiller J; O'Shaughnessy C; Mann JT; Turco M; Caputo R; Bergin P; Greenberg J; Popma JJ; Russell ME;
Circulation; 2004 Apr; 109(16):1942-7. PubMed ID: 15078803
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of the XIENCE V everolimus-eluting stent compared to first-generation drug-eluting stents in contemporary clinical practice.
Waksman R; Barbash IM; Dvir D; Torguson R; Ben-Dor I; Maluenda G; Xue Z; Satler LF; Suddath WO; Kent KM; Pichard AD
Am J Cardiol; 2012 May; 109(9):1288-94. PubMed ID: 22341925
[TBL] [Abstract][Full Text] [Related]
30. Sirolimus, Tacrolimus and Zotarolimus eluting stents to treat bifurcated lesions: a 7-month clinical outcome comparison.
Brugaletta S; Burzotta F; Trani C; Todaro D; Talarico G; Porto I; Leone AM; Niccoli G; Mazzari MA; Mongiardo R; Schiavoni G; Crea F
Minerva Cardioangiol; 2008 Feb; 56(1):35-42. PubMed ID: 18432167
[TBL] [Abstract][Full Text] [Related]
31. Three-year outcomes following sirolimus- versus paclitaxel-eluting stent implantation in an unselected population with coronary artery disease (from the REWARDS Registry).
Hanna NN; Gaglia MA; Torguson R; Ben-Dor I; Gonzalez MA; Collins SD; Syed AI; Maluenda G; Kaneshige K; Xue Z; Satler LF; Kent KM; Suddath WO; Pichard AD; Waksman R
Am J Cardiol; 2010 Aug; 106(4):504-10. PubMed ID: 20691308
[TBL] [Abstract][Full Text] [Related]
32. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease.
Stone GW; Rizvi A; Newman W; Mastali K; Wang JC; Caputo R; Doostzadeh J; Cao S; Simonton CA; Sudhir K; Lansky AJ; Cutlip DE; Kereiakes DJ;
N Engl J Med; 2010 May; 362(18):1663-74. PubMed ID: 20445180
[TBL] [Abstract][Full Text] [Related]
33. Two-year outcome of patients treated with sirolimus- versus paclitaxel-eluting stents in an unselected population with coronary artery disease (from the REWARDS Registry).
Roy P; Bonello L; de Labriolle A; Okabe T; Pinto Slottow TL; Steinberg DH; Torguson R; Smith K; Xue Z; Satler LF; Kent KM; Suddath WO; Pichard AD; Waksman R
Am J Cardiol; 2008 Aug; 102(3):292-7. PubMed ID: 18638589
[TBL] [Abstract][Full Text] [Related]
34. Percutaneous coronary intervention with everolimus-eluting stents (Xience V): systematic review and direct-indirect comparison meta-analyses with paclitaxel-eluting stents (Taxus) and sirolimus-eluting stents (Cypher).
Biondi-Zoccai G; Lotrionte M; Moretti C; Agostoni P; Sillano D; Laudito A; Sheiban I
Minerva Cardioangiol; 2008 Feb; 56(1):55-65. PubMed ID: 18432169
[TBL] [Abstract][Full Text] [Related]
35. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
[TBL] [Abstract][Full Text] [Related]
36. Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry).
Nienaber CA; Akin I; Schneider S; Senges J; Fetsch T; Tebbe U; Willich SN; Stumpf J; Sabin GV; Silber S; Richardt G; Kuck KH;
Am J Cardiol; 2009 Nov; 104(10):1362-9. PubMed ID: 19892051
[TBL] [Abstract][Full Text] [Related]
37. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization.
Windecker S; Remondino A; Eberli FR; Jüni P; Räber L; Wenaweser P; Togni M; Billinger M; Tüller D; Seiler C; Roffi M; Corti R; Sütsch G; Maier W; Lüscher T; Hess OM; Egger M; Meier B
N Engl J Med; 2005 Aug; 353(7):653-62. PubMed ID: 16105989
[TBL] [Abstract][Full Text] [Related]
38. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial.
Hermiller JB; Raizner A; Cannon L; Gurbel PA; Kutcher MA; Wong SC; Russell ME; Ellis SG; Mehran R; Stone GW;
J Am Coll Cardiol; 2005 Apr; 45(8):1172-9. PubMed ID: 15837245
[TBL] [Abstract][Full Text] [Related]
39. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice.
Dawkins KD; Grube E; Guagliumi G; Banning AP; Zmudka K; Colombo A; Thuesen L; Hauptman K; Marco J; Wijns W; Popma JJ; Koglin J; Russell ME;
Circulation; 2005 Nov; 112(21):3306-13. PubMed ID: 16286586
[TBL] [Abstract][Full Text] [Related]
40. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease. Study design and rationale of the EXECUTIVE trial.
Ribichini F; Ansalone G; Bartorelli A; Beqaraj F; Berni A; Colangelo S; D'Amico M; Della Rovere F; Fiscella A; Gabrielli G; Indolfi C; La Vecchia L; Loschiavo P; Marinoni G; Marzocchi A; Milazzo D; Romano M; Sangiorgio P; Sheiban I; Tamburino C; Tuccillo B; Villani R; Cappi B; Quijada MJ; Vassanelli C;
J Cardiovasc Med (Hagerstown); 2010 Apr; 11(4):299-309. PubMed ID: 20090550
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
